Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Tanezumab For Pain Turns Heads At Rheumatology Meeting

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm looking at 2011-2012 filing for drug candidate, now in Phase III.

You may also be interested in...



Pfizer/Lilly Had Big Ambitions For Tanezumab; Are They Finally Dashed?

Given serious safety questions with tanezumab, the US filing seemed like throwing a Hail Mary; two FDA advisory panels overwhelmingly rejected the proposed risk management plan.

Future Appears Grim For Pfizer's Tanezumab With Ostearthritis Trial Stopped

Because tanezumab is the anti-NGF farthest along in development, adverse event reports could spell trouble for the entire planned class of analgesics.

Future Appears Grim For Pfizer's Tanezumab With Ostearthritis Trial Stopped

Because tanezumab is the anti-NGF farthest along in development, adverse event reports could spell trouble for the entire planned class of analgesics.

Related Content

Topics

UsernamePublicRestriction

Register

PS066968

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel